Carcinoma of unknown primary (CUP): an update for histopathologists

被引:7
作者
Beauchamp, Katie [1 ]
Moran, Bruce [1 ]
O'Brien, Timothy [2 ]
Brennan, Donal [3 ,4 ]
Crown, John [5 ]
Sheahan, Kieran [1 ]
Cotter, Maura Brid [1 ]
机构
[1] St Vincents Univ Hosp, Dept Histopathol, Elm Pk, Dublin, Ireland
[2] Mater Misericordiae Univ Hosp, Dept Med Oncol, Dublin, Ireland
[3] UCD Sch Med, Syst Biol Ireland, Dublin, Ireland
[4] St Vincents Univ Hosp, UCD Gynaecol Oncol Grp, Elm Pk, Dublin, Ireland
[5] St Vincents Univ Hosp, Dept Med Oncol, Elm Pk, Dublin, Ireland
关键词
Carcinoma of unknown primary; Metastatic; Morphology; Pitfalls; Immunohistochemistry; Molecular pathology; PRIMARY SITE; COMPREHENSIVE ANALYSIS; MELAN-A; EXPRESSION; IMMUNOHISTOCHEMISTRY; MARKER; CELL; DIAGNOSIS; CYTOKERATIN-20; NEOPLASMS;
D O I
10.1007/s10555-023-10101-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carcinoma of unknown primary (CUP) is a heterogeneous group of metastatic cancers in which the site of origin is not identifiable. These carcinomas have a poor outcome due to their late presentation with metastatic disease, difficulty in identifying the origin and delay in treatment. The aim of the pathologist is to broadly classify and subtype the cancer and, where possible, to confirm the likely primary site as this information best predicts patient outcome and guides treatment. In this review, we provide histopathologists with diagnostic practice points which contribute to identifying the primary origin in such cases. We present the current clinical evaluation and management from the point of view of the oncologist. We discuss the role of the pathologist in the diagnostic pathway including the control of pre-analytical conditions, assessment of sample adequacy, diagnosis of cancer including diagnostic pitfalls, and evaluation of prognostic and predictive markers. An integrated diagnostic report is ideal in cases of CUP, with results discussed at a forum such as a molecular tumour board and matched with targeted treatment. This highly specialized evolving area ultimately leads to personalized oncology and potentially improved outcomes for patients.
引用
收藏
页码:1189 / 1200
页数:12
相关论文
共 67 条
[1]  
Affandi KA, 2018, J PATHOL TRANSL MED, V52, P283
[2]   Paraneoplastic syndromes-"keys" to histopathological diagnoses and appropriate therapy [J].
Agaimy, Abbas ;
Wick, Mark R. .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2019, 36 (04) :203-203
[3]   Incidence and Significance of GATA3 Positivity in Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma [J].
Agostini-Vulaj, Diana ;
Bratton, Laura E. ;
Dunne, Richard F. ;
Cates, Justin M. M. ;
Zhou, Zhongren ;
Findeis-Hosey, Jennifer J. ;
Yang, Qi ;
Ramesh, Mira K. ;
Gonzalez, Raul S. .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (06) :460-463
[4]  
Alshenawy HA, 2015, PATHOL ONCOL RES, V21, P893, DOI [10.1007/s12253-015-9898-7, 10.1016/j.jmau.2015.01.003]
[5]   Management of "unfavourable" carcinoma of unknown primary site: Synthesis of recent literature [J].
Amela, Eric Yaovi ;
Lauridant-Philippin, Geraldine ;
Cousin, Sophie ;
Ryckewaert, Thomas ;
Adenis, Antoine ;
Penel, Nicolas .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (02) :213-223
[6]  
[Anonymous], 2020, ONCOL PHARM
[7]   Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas [J].
Bayrak, Reyhan ;
Yenidunya, Sibel ;
Haltas, Hacer .
PATHOLOGY RESEARCH AND PRACTICE, 2011, 207 (03) :156-160
[8]  
Bonk Sarah, 2019, Oncotarget, V10, P5439, DOI 10.18632/oncotarget.27145
[9]   Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group study [J].
Briasoulis, E ;
Kalofonos, H ;
Bafaloukos, D ;
Samantas, E ;
Fountzilas, G ;
Xiros, N ;
Skarlos, D ;
Christodoulou, C ;
Kosmidis, F ;
Pavlidis, N .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3101-3107
[10]   Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract [J].
Cabibi, D ;
Licata, A ;
Barresi, E ;
Craxì, A ;
Aragona, F .
PATHOLOGY RESEARCH AND PRACTICE, 2003, 199 (02) :65-70